Kroger Pharmacy vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kroger-owned in-store pharmacy chain with 2,200 locations in supermarket banners; prescription services integrated with grocery loyalty program competing with CVS and Walgreens.
About
Kroger Pharmacy is the pharmacy division of The Kroger Co., operating approximately 2,200 in-store pharmacies within Kroger supermarkets and Kroger-owned banner stores (Fred Meyer, King Soopers, Ralphs, Harris Teeter, Smith's, and others) across the United States — making it one of the largest pharmacy chains in the country. Part of Kroger (NYSE: KR), the nation's largest pure-play supermarket chain with approximately $150 billion in annual revenue, Kroger Pharmacy benefits from the combination of convenient supermarket co-location and Kroger's pharmaceutical purchasing scale.\n\nKroger Pharmacy provides prescription filling, immunization services, medication therapy management, and specialty pharmacy for complex medications. The pharmacy integrates with Kroger's loyalty program (Kroger Plus Card) to provide fuel points for pharmacy purchases and to connect prescription refill reminders with grocery shopping behavior. Kroger's OptUP nutrition scoring and health programs connect pharmacy and grocery to support customer health goals.\n\nIn 2025, Kroger Pharmacy competes with CVS Health, Walgreens, Walmart Pharmacy, and mail-order pharmacies for prescription market share. The retail pharmacy sector faces significant pressure from PBM reimbursement cuts and the shift to 90-day mail-order supply, which has forced pharmacy closures across the industry. Kroger's merger with Albertsons (blocked by FTC in February 2024) would have significantly expanded Kroger's pharmacy network, but the blocked merger leaves Kroger competing at current scale. The 2025 strategy focuses on integrating pharmacy into Kroger's digital health ecosystem, expanding specialty pharmacy capabilities, and leveraging Kroger Health data analytics for population health management programs.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.